OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Investigational Drugs is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD	113
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	84
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	79
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL	74
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	73
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	69
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men	62
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	61
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	58
Theranostic strategies in sarcoma: preliminary clinical evidence	54
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	48
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	43
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	39
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	38
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	33
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	31
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	31
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	30
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	30
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	29
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	28
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	27
Investigational drugs for the treatment of dysmenorrhea	26
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	26
Potassium channel modulators and schizophrenia: an overview of investigational drugs	24